Director Craig Eagle of OS Therapies Inc filed a Form 4 on October 30, 2026, disclosing the grant of stock options to purchase 300,000 shares of common stock on October 22, 2026.

Key Highlights

  • Grant date: October 22, 2026, per the filing.
  • Options granted: 300,000 stock options (right to buy) with an exercise price of $1.25 per share.
  • Expiration date: October 22, 2036, according to the filing.
  • Vesting schedule: 12 equal monthly installments beginning on each monthly anniversary of the grant date, contingent on continued service as a director.
  • Price paid for the options: $0, as reported in the filing.
  • Beneficial ownership following the transaction: 300,000 derivative securities held directly.

OS Therapies Director Craig Eagle Receives October 2026 Option Award

According to the Form 4 filed with the U.S. Securities and Exchange Commission on October 30, 2026, Craig Eagle, a director of OS Therapies Inc (NASDAQ:OSTX), received a grant of stock options on October 22, 2026. The filing discloses that Eagle was granted options to purchase 300,000 shares of the issuer's common stock at an exercise price of $1.25 per share, with no cost paid to acquire the options.

The filing states that the options were granted "pursuant to the terms and conditions of a stock option award agreement and the issuer's amended and restated 2023 incentive compensation plan." The options are set to expire on October 22, 2036, giving them a ten-year term from the date of grant. According to the filing's explanation of responses, the award vests in 12 equal installments on each monthly anniversary of the grant date, provided that Eagle is serving as a director of the issuer on each applicable vesting date.

Following the reported transaction, the filing indicates that Eagle directly beneficially owns 300,000 derivative securities. No non-derivative securities were reported as acquired, disposed of, or beneficially owned in Table I of the filing. The transaction code recorded is "A," indicating an acquisition.

What Was Disclosed

Director Craig Eagle disclosed receipt of a stock option grant covering 300,000 shares of OS Therapies Inc common stock at a $1.25 exercise price, expiring October 22, 2036, and vesting in 12 equal monthly installments under the company's amended and restated 2023 incentive compensation plan.